by David Wallace Researchers have discovered a new therapeutic avenue targeting a protein called RSK1 (ribosomal protein S6 kinase A1), which could revolutionize treatment for blood cancers such as Myeloproliferative Neoplasms (MPN) and secondary Acute Myeloid Leukemia (sAML). This protein plays a crucial role in driving cancer progression and inflammation. The Drug’s Mechanism The investigational […]
How Does Polycythemia Vera Differ from Polycythemia?
by David Wallace Polycythemia: A Comprehensive Overview Polycythemia is defined as having an abnormally high number of red blood cells in the blood—derived from the Latin “poly” (many), “cyte” (cell), and “hemo” (blood). This general term encompasses various conditions leading to this hematological abnormality. Polycythemia Vera (PV) fits under this umbrella but has its own […]
New Scoring Model Improves Prediction of Outcomes in Essential Thrombocythemia
by David Wallace Summary: Researchers have developed a new Essential Thrombocythemia scoring system called the “triple A” (AAA) model to predict outcomes in patients with essential thrombocythemia (ET), a type of blood cancer. This model uses three simple factors: age, absolute neutrophil count, and absolute lymphocyte count to categorize patients into different risk groups. The […]
MPNs and Dementia Risk: New Study Finds Link Between Myeloproliferative Neoplasms and Cognitive Decline
by David Wallace A new study published in the European Journal of Haematology has uncovered a significant association between blood cancers known as myeloproliferative neoplasms (MPNs) and an increased risk of dementia. This Danish population-based cohort study, spanning over two decades, provides valuable insights into the long-term neurological impacts of chronic blood cancers and inflammation […]
The Unseen Journey: Bringing MPNs to Life with Generative AI
Sponsored Post Like countless busy parents juggling family responsibilities, when Ben began experiencing unexplained symptoms – such as headaches, fatigue and brain fog – he initially pushed them aside. Clarity only came when a physical exam for a new job uncovered something was wrong. Ben’s tests revealed he had an unexpectedly high platelet count. A […]
What Are The Key Factors in Predicting Polycythemia Vera Progression?
by David Wallace A new study has shed light on the factors that may predict polycythemia vera (PV) disease progression. The REVEAL study, presented at the 2024 European Hematology Association Congress, has identified five key characteristics that could help doctors better understand which patients are at higher risk of their condition worsening over time. Polycythemia […]
Honor those who make a difference in the myeloproliferative neoplasm community: Submit a nomination to the MPN Heroes® Recognition Program today!
Sponsored Post Living with a myeloproliferative neoplasm (MPN) can be emotionally and physically challenging, but individuals who bring hope, compassion and strength to the MPN community lessen this burden. The MPN community is rich with individuals who go to extraordinary lengths to make a meaningful difference—patients whose unwavering strength is an inspiration, caregivers who consistently […]
Precision Medicine in Myeloproliferative Neoplasms (MPNs): Molecular Insights and Advances
Simple Summary Myeloproliferative neoplasms (MPNs) represent a group of blood cancers characterized by the excessive production of blood cells in the bone marrow, including Polycythemia Vera (PV), Essential Thrombocythemia (ET), and Primary Myelofibrosis (PMF). Recent advancements in the field of molecular biology have significantly enhanced our understanding of the genetic underpinnings of these conditions. The […]
What Rare Disease Day Means to Me
by David Wallace Hi, my name is David, and I am a polycythemia vera (PV) warrior. PV is a rare blood cancer. To me, living with a rare disease is not just a medical journey; it’s a testament to resilience and the power of community. Rare Disease Day, for me, is more than just a […]
What is Blast Phase Myeloproliferative Neoplasm?
Abstract Leukemic transformation in myeloproliferative neoplasms (MPN), also referred to as “blast-phase MPN”, is the most feared disease complication, with incidence estimates of 1–4% for essential thrombocythemia, 3–7% for polycythemia vera, and 9–13% for primary myelofibrosis. Diagnosis of MPN-BP requires the presence of ≥20% circulating or bone marrow blasts; a lower level of excess blasts […]
- 1
- 2
- 3
- …
- 21
- Next Page »
